Drug Safety

, Volume 9, Issue 4, pp 272–279 | Cite as

Adverse Reactions with β-Adrenoceptor Blocking Drugs

An Update
  • Richard V. Lewis
  • Caroline Lofthouse
Review Article Drug Experience


β-Adrenoceptor blocking drugs are widely used throughout the world, and serious adverse reactions are relatively uncommon. Many of those that do occur, including bronchospasm and peripheral ischaemia, are due primarily to blockade of β2-adrenoceptors. Recently developed β blockers with enhanced β1-selectivity and partial β2-agonist activity appear, in general, to have lesser effects upon airways function and vascular resistance, but none are regarded as being entirely ‘safe’ in patients with asthma.

In the treatment of hypertensive patients with co-existing airways disease there are now effective alternatives to the β-blockers, including calcium antagonists, α-adrenoceptor antagonists and angiotensin converting enzyme (ACE) inhibitors. However, in the presence of ischaemic heart disease, β-blockers have specific advantages and may still be considered necessary in patients with airways disease. In this situation, agents with β2-agonist activity are preferable to ‘conventional’ β-blockers. However, there is still some risk that bronchospasm may occur in certain individuals, and the bronchodilator response to inhaled β2-agonists might be impaired.

In patients with peripheral vascular disease, β-blockers with β2-agonist activity are less likely to worsen the symptoms and signs of peripheral ischaemia, and may reduce the prevalence of peripheral coldness, a common adverse effect of β-blockers.

There is concern that β-blockers may have significant central effects, including impairment of memory and concentration, although these are difficult to quantify. A number of pharmacologically unpredictable adverse reactions may occur rarely, including skin reactions, alopecia and arthropathy.


Atenolol Bisoprolol Celiprolol Bronchodilator Response Dilevalol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bailliart O, Kedra AW, Bonnin P, Savin E, Martineaud J-P. Effects of bisoprolol on local vascular resistance. European Heart Journal 8(Suppl. M): 87–93, 1987PubMedGoogle Scholar
  2. Barnett DB, Rugg EL, Nahorski SR. Direct evidence of two types of beta-adrenoceptor binding site in lung tissue. Nature 273: 166–168, 1978PubMedCrossRefGoogle Scholar
  3. Bassotti G, Gaburri M, Pelli MA, Morelli A. Oesophageal pain exacerbated by propranolol. British Medical Journal 294: 1655, 1987PubMedCrossRefGoogle Scholar
  4. Bolli P, Muller FB, Linder L, Ji BH, Buhler FR. Cardiac and vascular β-adrenoceptor mediated responses before and during treatment with bisoprolol or atenolol. Journal of Cardiovascular Pharmacology 8(Suppl. 11): S61–S64, 1986PubMedGoogle Scholar
  5. Bright RA, Everitt DE. β-Blockers and depression: evidence against an association. Journal of the American Medical Association 267: 1783–1787, 1992PubMedCrossRefGoogle Scholar
  6. Bruschi C, Casali L, Cerveri I, Peona V, Zoia M. Effects of Celiprolol on the bronchial reactivity in asthma. American Journal of Cardiology 62: 24c–29c, 1988CrossRefGoogle Scholar
  7. Buhler FR, Berglund G, Anderson OK. Double blind comparison of the cardioselective β-blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study. Journal of Cardiovascular Pharmacology 8(Suppl. 11): 122–127, 1986Google Scholar
  8. Capone P, Mayol R, Mathieu M. A comparative study of Celiprolol and chlorthalidone in hypertensive patients with reversible airways obstruction. British Journal of Clinical Practice 40 (Suppl.): 37–39, 1985PubMedGoogle Scholar
  9. Chang LCT. Use of practolol in asthmatics: a plea for caution. Lancet 2: 321, 1971PubMedCrossRefGoogle Scholar
  10. Chatterjee SS. The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. Journal of Cardiovascular Pharmacology 8(Suppl. 11): S74–S77, 1986PubMedGoogle Scholar
  11. Chiasmi-Pasha H, Taylor RJ, Barnes PC. Beta-blockers, lipids and coronary atherosclerosis. Correspondence. British Medical Journal 1: 1130, 1988CrossRefGoogle Scholar
  12. Currie D, Lewis RV, McDevitt DG, Nicholson AN, Wright NA. Central effects of β-adrenoceptor antagonists. 1 — Performance and subjective assessments of mood. British Journal of Clinical Pharmacology 26: 121–128, 1988PubMedCrossRefGoogle Scholar
  13. Deacon SP, Barnett D. Comparison of atenolol and propranolol during insulin induced hypoglycaemia. British Medical Journal 2: 272, 1976PubMedCrossRefGoogle Scholar
  14. Dorrow P, Bethge H, Tonnesmann V. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. European Journal of Clinical Pharmacology 31: 143–147, 1986CrossRefGoogle Scholar
  15. England JD, Simons LH, Gibson JC, Carton M. The effects of metoprolol and atenolol on plasma high density lipoprotein levels in man. Clinical and Experimental Pharmacology and Physiology 7: 329–333, 1980PubMedCrossRefGoogle Scholar
  16. Fogari R, Zoppi A, Pasotti C, Poletti L, Tettamanti F, et al. Effects of different beta-blockers on lipid metabolism in chronic therapy of hypertension. International Journal of Clinical Pharmacology, Therapy and Toxicology 26: 597–604, 1988Google Scholar
  17. Fowler MB. Beta-blockers in heart failure. Journal of Human Hypertension 7(Suppl. 1): S62–S67, 1993PubMedGoogle Scholar
  18. Fraley DS, Bruns FJ, Segal DP, Adler S. Propranolol related bronchospasm in patients without history of asthma. Southern Medical Journal 73: 238, 1976CrossRefGoogle Scholar
  19. Frishman WH, Flamenbaum W, Schoenberger J. Celiprolol in systemic hypertension. American Journal of Cardiology 63: 839–842, 1989PubMedCrossRefGoogle Scholar
  20. Frithz G, Weiner L. Long-term effects of bisoprolol on blood pressure, serum lipids, and HDL-cholesterol in patients with essential hypertension. Journal of Cardiovascular Pharmacology 8(Suppl. 11): S134–S138, 1986PubMedGoogle Scholar
  21. Gokal R, Dornan RL, Ledingham JGG. Peripheral skin necrosis complicating beta-blockade. British Medical Journal 1: 721, 1979PubMedCrossRefGoogle Scholar
  22. Gold MH, Holy AK, Roenigk Jr HH. Beta-blocking drugs and psoriasis. Journal of the American Academy of Dermatology 19: 837–841, 1988PubMedCrossRefGoogle Scholar
  23. Haeusler G. High selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol. Journal of Cardiovascular Pharmacology 8(Suppl. 11): S2–S15, 1986PubMedGoogle Scholar
  24. Hedner J, Ullman A, Lemne C, Svedmyr N. Effects of dilevalol, a beta-adrenoceptor antagonist with intrinsic symptathetic activity in asthmatic patients. Pulmonary Pharmacology 2: 155–159, 1989PubMedCrossRefGoogle Scholar
  25. Heng MCY, Heng MK. Beta-adrenoceptor antagonist induced psoriasiform eruption. International Journal of Dermatology 27: 619–627, 1988PubMedCrossRefGoogle Scholar
  26. Hughes A, Martin G, Goldberg P, Thom S, Sever P. No evidence for a direct vasodilatory effect of celiprolol on human vasculature in vivo or in vitro. Journal of Cardiovascular Pharmacology 10: 589–592, 1987PubMedCrossRefGoogle Scholar
  27. Kurihara N, Fujimoto S, Hirata K, Takeda T, Yamamoto K. Effect of Celiprolol, a new beta-1 blocker, on respiratory function in bronchial asthmatic patients in single dose. From the point of view of double blind study vs metoprolol and placebo. Rinsho Iyaku 5: 2367–2379, 1989Google Scholar
  28. Lammers JWJ, Folgering HT, van Herwaarden CLA. Ventilatory effects of long term treatment with pindolol and metoprolol in hypertensive patients with chronic obstructive lung disease. British Journal of Clinical Pharmacology 20: 205–210, 1985PubMedCrossRefGoogle Scholar
  29. Lang DM, Alpern MB, Visintainer PF, Smith ST. Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Annals of Internal Medicine 15: 270–276, 1991Google Scholar
  30. Lepantalo M. Effects of metoprolol and alpha methyldopa on calf blood flow. British Journal of Clinical Pharmacology 18: 90–93, 1984PubMedCrossRefGoogle Scholar
  31. Lertora JJ, Mark AL, Johanssen J, Wilson WR, Abboud FM. Selective beta-1 receptor blockade with oral practolol in man. Journal of Clinical Investigation 56: 719–723, 1975PubMedCrossRefGoogle Scholar
  32. Lewis RV, Jackson PR, Ramsay LE. Quantification of side effects of beta-adrenoceptor blocking drugs using visual analogue scales. British Journal of Clinical Pharmacology 18: 325–330, 1984PubMedCrossRefGoogle Scholar
  33. Lewis RV, Maclean D, Ioannides C, Johnston A, McDevitt DG. A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension. British Journal of Clinical Pharmacology 26: 53–59, 1988PubMedCrossRefGoogle Scholar
  34. Lewis RV, McDevitt DG. Adverse reactions and interactions with beta-adrenoceptor blocking drugs. Medical Toxicology 1: 343–361, 1986PubMedGoogle Scholar
  35. Lichter I, Richardson PJ, Wyke MA. Differential effects of atenolol and enalapril on memory during treatment for essential hypertension. British Journal of Clinical Pharmacology 21: 641–645, 1986PubMedCrossRefGoogle Scholar
  36. Matsunaga K, Nakamura K, Ueda M. Intrinsic beta-sympathomimetic activity of dilevalol, RR isomer of labetolol. Journal of Pharmacobiology 8: 785–787, 1985CrossRefGoogle Scholar
  37. Matthys H, Doshan HD, Ruhle KH, Applin WJ, Braig H, et al. Bronchosparing properties of Celiprolol, a new beta-1 alpha-2 blocker, in propranolol-sensitive asthmatic patients. Journal of Cardiovascular Pharmacology 8(Suppl. 4): S40–S42, 1986PubMedCrossRefGoogle Scholar
  38. Milne RJ, Buckley M. Celiprolol: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease. Drugs 41: 941–969, 1991PubMedCrossRefGoogle Scholar
  39. Modersohn D, Franz N, Heublein B, Panzner B. Acute haemodynamic profile of Celiprolol in patients with coronary heart disease and hypertension: a double-blind comparison with metoprolol. European Heart Journal 12: 617–623, 1991PubMedGoogle Scholar
  40. Otsuka K, Tsukiyama H. Haemodynamic effects of Celiprolol, a beta-1 selective beta-adrenoceptor blocking agent with beta-2 selective ISA in patients with essential hypertension. Rinsho Iyaku 6: 73–80, 1990Google Scholar
  41. Pedersen DL. Hymenopetra stings and beta-blockers. Correspondence. Lancet 2: 916, 1989Google Scholar
  42. Pujet JC, Dubeuil C, Fleury B, Provendier O, Abella ML. Effects of Celiprolol, a cardioselective beta-blocker, on respiratory function in asthmatic patients. European Respiratory Journal 5: 196–200, 1992PubMedGoogle Scholar
  43. Richards S. Cutaneous side effects of beta-adrenoceptor blockers. Australian Journal of Dermatology 26: 25–28, 1985CrossRefGoogle Scholar
  44. Shaw J, England JD, Hua AS. Beta-blockers and plasma triglycerides. British Medical Journal 1: 986, 1978PubMedCrossRefGoogle Scholar
  45. Solomon S, Hotchkiss E, Saravay SM, Bayer C, Ramsay P, et al. Impairment of memory function by antihypertensive medication. Archives of General Psychiatry 41: 1109–1112, 1983CrossRefGoogle Scholar
  46. Stringer MD, Bentley PG. Peripheral gangrene associated with beta-blockade. British Journal of Surgery 73: 1008, 1986PubMedCrossRefGoogle Scholar
  47. Tanaka N, Sakaguchi S, Oshige K, Namura T, Kanehisa T. Effects of chronic administration of propranolol on lipoprotein composition. Metabolism 25: 1071–1075, 1976PubMedCrossRefGoogle Scholar
  48. Trimarco B, Lembo G, De Luca N, Ricciardellii B, Rosiello G, et al. Effects of Celiprolol on systemic and forearm circulation in hypertensive patients; a double blind cross-over study versus metoprolol. Journal of Clinical Pharmacology 27: 593–600, 1987PubMedGoogle Scholar
  49. van Zwieten PA. The role of adrenoceptors in circulatory and metabolic regulation. American Heart Journal 116: 1384–1392, 1988PubMedCrossRefGoogle Scholar
  50. van Zyl AI, Jennings AA, Bateman ED, Opie LH. Comparison of the respiratory effects of two cardioselective beta-blockers, Celiprolol and atenolol, in asthmatics with mild to moderate hypertension. Chest 95: 209–213, 1989PubMedCrossRefGoogle Scholar
  51. Vyssoulis G, Karpanou EA, Pitsavos V, Skoumas J, Paleologos AA. Pulmonary blood flow changes after a single oral dose of first and third generation beta-blockers in hypertensives. Abstract. European Heart Journal 10 (Suppl.): 306, 1989Google Scholar
  52. Waal HJ. Propranol-induced depression. British Medical Journal 2: 50, 1967PubMedCrossRefGoogle Scholar
  53. Waal Manning HJ, Simpson FO. Safety of Celiprolol in hypertensives with chronic obstructive respiratory disease. New Zealand Medical Journal 103: 222, 1990Google Scholar
  54. Walden RJ, Tomlinson B, Graham B, Liu JB, Prichard BNC. Withdrawal phenomena after atenolol and bopindolol: haemodynamic responses in healthy volunteers. British Journal of Clinical Pharmacology 30: 557–565, 1990PubMedCrossRefGoogle Scholar
  55. Wolf PS, Smith RD, Jolly SR, Pruss TP. Comparison of Celiprolol with yohimbine and prazosin in ganglionic beta-blocked dogs. Pharmacologist 27: 112, 1985Google Scholar
  56. Yudofsky SC. Beta-blockers and depression. Journal of the American Medical Association 267: 1826–1827, 1992PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Richard V. Lewis
    • 1
  • Caroline Lofthouse
    • 1
  1. 1.Pontefract General InfirmaryPontefractEngland

Personalised recommendations